文献速递区域麻醉与超声术前评估与围术期医学

右美托咪定作为锁骨上臂丛阻滞局麻药佐剂优于可乐定:系统评价与荟萃分析

Perineural Dexmedetomidine Is More Effective Than Clonidine When Added to Local Anesthetic for Supraclavicular Brachial Plexus Block: A Systematic Review and Meta-analysis.
PubMed 文献 · Anesth Analg · 2017-01-01

该系统评价与荟萃分析纳入14项随机对照试验共868例患者,比较右美托咪定与可乐定作为单次锁骨上臂丛阻滞局麻药佐剂的效果。右美托咪定延长感觉、运动阻滞及镇痛持续时间,加快阻滞起效,但增加一过性心动过缓和术后镇静风险。

要点

  • 右美托咪定较可乐定延长感觉阻滞持续时间约1.2倍。
  • 右美托咪定加快感觉和运动阻滞起效,并延长镇痛持续时间。
  • 右美托咪定增加一过性心动过缓和术后镇静风险,需权衡利弊。

核心结论

  • 与可乐定相比,右美托咪定作为单次锁骨上臂丛阻滞局麻药佐剂可改善感觉、运动和镇痛阻滞特征。
  • 这些获益需与一过性心动过缓风险增加相权衡。

研究设计与样本

  • 系统评价与荟萃分析,纳入14项随机对照试验,共868例患者,比较右美托咪定与可乐定作为单次锁骨上臂丛阻滞局麻药佐剂。
  • 主要结局为感觉阻滞持续时间,采用随机效应模型和均值比进行合并分析。

临床怎么用

  • 在单次锁骨上臂丛阻滞中,若追求更长阻滞和镇痛时间,可优先考虑右美托咪定作为局麻药佐剂。
  • 使用右美托咪定时应警惕一过性心动过缓和术后镇静,需加强监测。
  • 其他α-2激动剂相关副作用及阻滞相关并发症在两种药物间无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clonidine, an α-2 agonist, has long been used as a local anesthetic adjunct with proven efficacy to prolong peripheral nerve block duration. Dexmedetomidine, a newer α-2 agonist, has a more favorable pharmacodynamic and safety profile; however, data comparing its efficacy as an adjunct to that of clonidine are inconsistent. We sought to compare the clinical efficacy of these 2 α-2 agonists by examining their effects on peripheral nerve block characteristics for upper extremity surgery. METHODS: A preliminary search found that the overwhelming majority of randomized controlled trials comparing perineural dexmedetomidine to clonidine for upper extremity surgery were in the setting of supraclavicular brachial plexus block (SCB). Therefore, we performed a systematic review and meta-analysis of randomized controlled trials comparing dexmedetomidine with clonidine as perineural adjuncts to single-injection SCB. Sensory and motor block duration and onset, analgesic duration, α-2 agonist side effects, and block complications were analyzed. Sensory block duration was designated as a primary outcome. Data were combined using random-effects modeling, and ratio-of-means was used to analyze the results. RESULTS: A total of 868 patients from 14 clinical studies were included in the analysis. Compared with clonidine, dexmedetomidine prolonged the duration (ratio of means [95% confidence interval {CI}]) of sensory block by an estimate of 1.2 (1.2-1.3; P< .00001). It also prolonged the duration (ratio of means [99% CI]) of motor block by an estimate of 1.2 (1.1-1.3; P < .00001), and analgesia by an estimate of 1.2 (1.1-1.3; P < .00001). It also hastened the onset of sensory block by an estimate of 0.9 (0.8-1.0; P < .00001) and motor block by an estimate of 0.9 (0.9-1.0; P = .002). Dexmedetomidine was associated with an increased odds ratio (99% CI) of transient bradycardia by an estimate of 7.4 (1.3-40.8; P = .003) and postoperative sedation by an estimate of 11.8 (1.9-73.6; P = .0005). There were no differences in other α-2 agonist-related side effects or block-related complications. CONCLUSIONS: Compared with clonidine as a local anesthetic adjunct for single-injection SCB, perineural dexmedetomidine enhances sensory, motor, and analgesic block characteristics. These benefits should be weighed against the increased risk of transient bradycardia.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. El-Boghdadly K, Brull R, Sehmbi H, et al. Perineural Dexmedetomidine Is More Effective Than Clonidine When Added to Local Anesthetic for Supraclavicular Brachial Plexus Block: A Systematic Review and Meta-analysis. Anesth Analg. 2017. PMID: 28525514. doi:10.1213/ANE.0000000000002014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。